VitsGen Therapeutics

VitsGen Therapeutics is a biopharmaceutical company focused on developing novel small molecule therapies to treat vascular diseases by targeting the Tie2 signaling pathway. The company's lead programs aim to restore vascular stability and reduce leakage in conditions such as diabetic macular edema and wet age-related macular degeneration. By utilizing a unique mechanism of Tie2 activation, VitsGen seeks to provide more effective and durable treatments compared to current anti-VEGF therapies. The company is also exploring the application of its technology in systemic vascular diseases, including acute respiratory distress syndrome and sepsis. VitsGen is led by Dr. Kevin Peters, a recognized expert in Tie2 biology and vascular medicine.